Sol-Gel Technologies (NASDAQ: SLGL) has seen its target price dramatically increased from $6.00 to $50.00 by HC Wainwright, according to a research note released on Monday. The investment firm has also assigned a buy rating to the stock, reflecting a positive outlook on the company’s future performance.
In addition to the target price adjustment, HC Wainwright provided earnings forecasts for Sol-Gel Technologies for the upcoming quarters. The firm estimates that the company will report a loss of ($2.09) earnings per share (EPS) for the third quarter of 2025, with a projected recovery leading to a profit of $0.40 EPS in the fourth quarter. For the full fiscal year of 2025, a loss of ($0.68) EPS is expected. Earnings forecasts for 2026 predict continued losses, with Q1 at ($1.63) EPS, Q2 at ($1.74) EPS, Q3 at ($1.78) EPS, and Q4 at ($1.47) EPS, culminating in a projected annual loss of ($6.60) EPS.
Other analysts have also expressed their views on Sol-Gel Technologies. Weiss Ratings reaffirmed a hold (C-) rating on October 8, 2023, while Wall Street Zen upgraded the stock to a buy rating on September 13, 2023. Currently, there is a consensus rating of Moderate Buy with an average target price of $50.00, according to MarketBeat.com.
The latest quarterly earnings report from Sol-Gel Technologies, released on August 15, 2023, revealed a surprising performance. The company posted earnings of $4.17 EPS for the quarter, significantly exceeding the consensus estimate of ($0.67) EPS by $4.84. Despite this, the company reported a negative return on equity of 11.80% and a net margin of 14.25%. Revenue for the quarter reached $17.26 million, well above analyst expectations of $2.86 million.
Looking ahead, sell-side analysts are predicting a modest improvement for Sol-Gel Technologies, forecasting an EPS of ($0.28) for the current fiscal year.
Founded in Israel, Sol-Gel Technologies Ltd. develops topical dermatological treatments for patients with severe skin conditions. The company’s product offerings include Twyneo, a once-daily non-antibiotic topical cream designed for the treatment of acne vulgaris, and Epsolay, a topical cream aimed at treating papulopustular rosacea.
As Sol-Gel Technologies continues to navigate its path forward, the recent uptick in target price reflects growing confidence among analysts in the company’s potential to deliver on its ambitious goals.
